

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

**EP 0 861 850 A1**

(12)

## EUROPEAN PATENT APPLICATION

(43) Date of publication:  
02.09.1998 Bulletin 1998/36

(51) Int Cl.<sup>5</sup>: **C07K 14/525, C07K 14/71,  
C12N 15/11, C12N 15/28**

(21) Application number: **98300382.3**

(22) Date of filing: **20.01.1998**

(84) Designated Contracting States:  
**AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC  
NL PT SE**

(30) Priority: **04.02.1997 US 794796**

(71) Applicant: **SMITHKLINE BEECHAM  
CORPORATION  
Philadelphia Pennsylvania 19103 (US)**

(72) Inventors:  
• **Emery, John  
King of Prussia, Pennsylvania 19406 (US)**

• **Tan, Kong B.  
King of Prussia, Pennsylvania 19406 (US)**  
• **Truneh, Alemseged  
King of Prussia, Pennsylvania 19406 (US)**  
• **Young, Peter R.  
King of Prussia, Pennsylvania 19406 (US)**

(74) Representative: **Crump, Julian Richard John et al  
1J Cleveland,  
40-43 Chancery Lane  
London WC2A 1JQ (GB)**

(54) **Tumor necrosis related receptor, TR4**

(57) TR4 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing TR4 polypeptides and polynucleotides in the design of protocols for the treatment of chronic and acute inflammation, arthritis, septicemia,

autoimmune diseases (eg inflammatory bowel disease, psoriasis), transplant rejection, graft vs. host disease, infection, stroke, ischemia, acute respiratory disease syndrome, restenosis, brain injury, AIDS, Bone diseases, cancer (eg lymphoproliferative disorders), atherosclerosis and Alzheimers disease, among others, and diagnostic assays for such conditions.

**EP 0 861 850 A1**

## Description

## FIELD OF INVENTION

5 This invention relates to newly identified polynucleotides, polypeptides encoded by them and to the use of such polynucleotides and polypeptides, and to their production. More particularly, the polynucleotides and polypeptides of the present invention relate to Tumor necrosis factor receptor (TNF-R) family, hereinafter referred to as TR4. The invention also relates to inhibiting or activating the action of such polynucleotides and polypeptides.

## 10 BACKGROUND OF THE INVENTION

Many biological actions, for instance, response to certain stimuli and natural biological processes, are controlled by factors, such as cytokines. Many cytokines act through receptors by engaging the receptor and producing an intra-cellular response.

15 For example, tumor necrosis factors (TNF) alpha and beta are cytokines which act through TNF receptors to regulate numerous biological processes, including protection against infection and induction of shock and inflammatory disease. The TNF molecules belong to the "TNF-ligand" superfamily, and act together with their receptors or counter-ligands, the "TNF-receptor" superfamily. So far, nine members of the TNF ligand superfamily have been identified and ten members of the TNF-receptor superfamily have been characterized.

20 Among the ligands there are included TNF-a, lymphotoxin-a (LT-a, also known as TNF-b), LT-b (found in complex heterotrimer LT-a2-b), FasL, CD40L, CD27L, CD30L, 4-1BBL, OX40L and nerve growth factor (NGF)). The superfamily of TNF receptors includes the p55TNF receptor, p751-TNF receptor, TNF receptor-related protein, FAS antigen or APO-1, CD40, CD27, CD30, 4-1BB, OX40, low affinity p75 and NGF-receptor (Meager, A., Biologicals, 22:291-295 (1994)).

25 Many members of the TNF-ligand superfamily are expressed by activated T-cells, implying that they are necessary for T-cell interactions with other cell types which underlie cell ontogeny and functions. (Meager, A., supra).

Considerable insight into the essential functions of several members of the TNF receptor family has been gained from the identification and creation of mutants that abolish the expression of these proteins. For example, naturally occurring mutations in the FAS antigen and its ligand cause lymphoproliferative disease (Watanabe-Fukunaga, R., et al. Nature 356:314 (1992)), perhaps reflecting a failure of programmed cell death. Mutations of the CD40 ligand cause an X-linked immunodeficiency state characterized by high levels of immunoglobulin M and low levels of immunoglobulin G in plasma, indicating faulty T-cell-dependent B-cell activation (Allen, R.C. et al., Science 259:990 (1993)). Targeted mutations of the low affinity nerve growth factor receptor cause a disorder characterized by faulty sensory innervation of peripheral structures (Lee, K.F. et al. Cell 69:737 (1992)).

35 TNF and LT-a are capable of binding to two TNF receptors (the 55- and 75-kd TNF receptors). A large number of biological effects elicited by TNF and LT-a, acting through their receptors, include hemorrhagic necrosis of transplanted tumors, cytotoxicity, a role in endotoxic shock, inflammation, immunoregulation, proliferation and anti-viral responses, as well as protection against the deleterious effects of ionizing radiation. TNF and LT-a are involved in the pathogenesis of a wide range of diseases, including endotoxic shock, cerebral malaria, tumors, autoimmune disease, AIDS and graft-host rejection (Beutler, B. and Von Huffel, C. Science 264:667-668 (1994)). Mutations in the p55 Receptor cause increased susceptibility to microbial infection.

Moreover, an about 80 amino acid domain near the C-terminus of TNFR1 (P55) and Fas was reported as the "death domain" which is responsible for transducing signals for programmed cell death (Tartaglia et al., Cell 74:845 (1993)).

45 The effects of TNF family ligands and TNF family receptors are varied and influence numerous functions, both normal and abnormal, in the biological processes of the mammalian system. There is a clear need, therefore, for identification and characterization of such receptors and ligands that influence biological activity, both normally and in disease states. In particular, there is a need to isolate and characterize novel members of the TNF receptor family.

50 This indicates that these Tumor necrosis factor receptors (TNF-R) have an established, proven history as therapeutic targets. Clearly there is a need for identification and characterization of further members of Tumor necrosis factor receptor (TNF-R) family which can play a role in preventing, ameliorating or correcting dysfunctions or diseases, including but not limited to chronic and acute inflammation, arthritis, septicemia, autoimmune diseases (eg inflammatory bowel disease, psoriasis), transplant rejection, graft vs. host disease, infection, stroke, ischemia, acute respiratory disease syndrome, restenosis, brain injury, AIDS, Bone diseases, cancer (eg lymphoproliferative disorders), atherosclerosis, and Alzheimers disease.

## SUMMARY OF THE INVENTION

In one aspect, the invention relates to TR4 polypeptides and recombinant materials and methods for their production. Another aspect of the invention relates to methods for using such TR4 polypeptides and polynucleotides. Such uses include the treatment of chronic and acute inflammation, arthritis, septicemia, autoimmune diseases (eg inflammatory bowel disease, psoriasis), transplant rejection, graft vs. host disease, infection, stroke, ischemia, acute respiratory disease syndrome, restenosis, brain injury, AIDS, Bone diseases, cancer (eg lymphoproliferative disorders), atherosclerosis, and Alzheimers disease, among others. In still another aspect, the invention relates to methods to identify agonists and antagonists using the materials provided by the invention, and treating conditions associated with TR4 imbalance with the identified compounds. Yet another aspect of the invention relates to diagnostic assays for detecting diseases associated with inappropriate TR4 activity or levels.

## BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the nucleotide and deduced amino acid sequence of human TR4. SEQ ID NOS: 1 and 2.

## DESCRIPTION OF THE INVENTION

Definitions

20

The following definitions are provided to facilitate understanding of certain terms used frequently herein.

"TR4" refers generally to a polypeptide having the amino acid sequence set forth in SEQ ID NO:2 or an allelic variant thereof.

"TR4 activity or TR4 polypeptide activity" or "biological activity of the TR4 or TR4 polypeptide" refers to the metabolic or physiologic function of said TR4 including similar activities or improved activities or these activities with decreased undesirable side-effects. Also included are antigenic and immunogenic activities of said TR4.

"TR4 polypeptides" refers to polypeptides with amino acid sequences sufficiently similar to TR4 sequences, preferably exhibiting at least one biological activity of the TR4.

"TR4 gene" refers to a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 1 or allelic variants thereof and/or their complements.

"TR4 polynucleotides" refers to polynucleotides containing a nucleotide sequence which encodes a TR4 polypeptide or fragment thereof, or a nucleotide sequence which has at least 58% identity to a nucleotide sequence encoding the polypeptide of SEQ ID NO:2 or the corresponding fragment thereof, or a nucleotide sequence which has sufficient identity to a nucleotide sequence contained in SEQ ID NO: 1 to hybridize under conditions useable for amplification or for use as a probe or marker.

"Antibodies" as used herein includes polyclonal and monoclonal antibodies, chimeric, single chain, and humanized antibodies as well as Fab fragments including the products of an Fab or other immunoglobulin expression library

"Isolated" means altered "by the hand of man" from the natural state. If an "isolated" composition or substance occurs in nature, it has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally present in a living animal is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated" as the term is employed herein.

"Polynucleotide" generally refers to any polyribonucleotide or polydeoxyribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. "Polynucleotides" include, without limitation single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, "polynucleotide" refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term polynucleotide also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications has been made to DNA and RNA, thus "polynucleotide" embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells. "Polynucleotide" also embraces relatively short polynucleotides, often referred to as oligonucleotides.

"Polypeptide" refers to any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres. "Polypeptide" refers to both short chains, commonly referred to as peptides, oligopeptides or oligomers, and to longer chains, generally referred to as proteins. Polypeptides may contain amino acids other than the 20 gene-encoded amino acids. "Polypeptides" include amino acid sequences modified either by natural processes, such as posttranslational processing, or by chemical modification techniques which

are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched and branched cyclic polypeptides may result from posttranslational natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. See, for instance, PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York, 1993 and Wold, F., Posttranslational Protein Modifications: Perspectives and Prospects, pgs. 1-12 in POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, 1983; Seifter *et al.*, "Analysis for protein modifications and nonprotein cofactors", *Meth Enzymol* (1990) 182:626-646 and Rattan *et al.*, "Protein Synthesis: Posttranslational Modifications and Aging", *Ann NY Acad Sci* (1992) 663:48-62.

"Variant" as the term is used herein, is a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide respectively, but retains essential properties. A typical variant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, additions, deletions in any combination. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. A variant of a polynucleotide or polypeptide may be a naturally occurring such as an allelic variant, or it may be a variant that is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques or by direct synthesis.

"Identity" is a measure of the identity of nucleotide sequences or amino acid sequences. In general, the sequences are aligned so that the highest order match is obtained. "Identity" *per se* has an art-recognized meaning and can be calculated using published techniques. See e.g. (COMPUTATIONAL MOLECULAR BIOLOGY, Lesk, A.M., ed., Oxford University Press, New York, 1988; BIOCOMPUTING INFORMATICS AND GENOME PROJECTS, Smith, D.W., ed., Academic Press, New York, 1993; COMPUTER ANALYSIS OF SEQUENCE DATA, PART I, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; SEQUENCE ANALYSIS IN MOLECULAR BIOLOGY, von Heinje, G., Academic Press, 1987, and SEQUENCE ANALYSIS PRIMER, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991). While there exist a number of methods to measure identity between two polynucleotide or polypeptide sequences, the term "identity" is well known to skilled artisans (Carillo, H., and Lipton, D., *SIAM J Applied Math* (1988) 48:1073). Methods commonly employed to determine identity or similarity between two sequences include, but are not limited to, those disclosed in Guide to Huge Computers, Martin J. Bishop, ed., Academic Press, San Diego, 1994, and Carillo, H., and Lipton, D., *SIAM J Applied Math* (1988) 48:1073. Methods to determine identity and similarity are codified in computer programs. Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, GCS program package (Devereux, J., *et al.*, *Nucleic Acids Research* (1984) 12(1):387), BLASTP, BLASTN, FASTA (Atschul, S.F. *et al.*, *J Molec Biol* (1990) 215:403).

#### Polypeptides of the invention

The TR4 polypeptides of the present invention include the polypeptide of SEQ ID NO:2 (in particular the mature polypeptide) as well as TR4 polypeptides which have at least 80% identity to the polypeptide of SEQ ID NO:2 or the relevant portion and more preferably at least 85% identity, and still more preferably at least 90% identity, and even still more preferably at least 95% identity to SEQ ID NO:2.

The TR4 polypeptides may be in the form of the "mature" protein or may be a part of larger protein such as a fusion protein. It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification such as multiple histidine residues, or an additional sequence for stability during recombinant production.

Biologically active fragments of the TR4 polypeptides are also included in the invention. A fragment is a polypeptide having an amino acid sequence that entirely is the same as part, but not all, of the amino acid sequence of the aforementioned TR4 polypeptides. As with TR4 polypeptides, fragments may be "free-standing," or comprised within a larger polypeptide of which they form a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments of the invention, include, for example, fragments from about amino acid number 1-20, 21-40, 41-60, 61-80, 81-100, and 101 to the end of TR4 polypeptide. In this context "about" includes the particularly recited ranges larger or smaller by several, 5, 4, 3, 2 or 1 amino acid at either extreme or at both extremes.

Preferred fragments include, for example, truncation polypeptides having the amino acid sequence of TR4 polypeptides, except for deletion of a continuous series of residues that includes the amino terminus, or a continuous series of residues that includes the carboxyl terminus or deletion of two continuous series of residues, one including the amino terminus and one including the carboxyl terminus. Also preferred are fragments characterized by structural or functional attributes such as fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions. Biologically active fragments are those that mediate TR4 activity, including those with a similar activity, or an improved activity, or with a decreased undesirable activity. Also included are those that are antigenic or immunogenic in an animal, especially in a human.

Thus, the polypeptides of the invention include polypeptides having an amino acid sequence at least 80% identical to that of SEQ ID NO:2 or fragments thereof with at least 80% identity to the corresponding fragment of SEQ ID NO:2. Preferably, all of these polypeptides retain the biological activity of the TR4, including antigenic activity. Included in this group are variants of the defined sequence and fragments. Preferred variants are those that vary from the referents by conservative amino acid substitutions -- i.e., those that substitute a residue with another of like characteristics. Typical such substitutions are among Ala, Val, Leu and Ile; among Ser and Thr; among the acidic residues Asp and Glu; among Asn and Gln; and among the basic residues Lys and Arg; or aromatic residues Phe and Tyr. Particularly preferred are variants in which several, 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination.

The TR4 polypeptides of the invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

#### Polynucleotides of the Invention

Another aspect of the invention relates to isolated polynucleotides which encode the TR4 polypeptides and polynucleotides closely related thereto.

TR4 of the invention is structurally related to other proteins of the Tumor necrosis factor receptor (TNF-R), as shown by the results of sequencing the cDNA encoding human TR4. The cDNA sequence contains an open reading frame encoding a protein of 300 with a deduced molecular weight of 32.7 kDa. TR4 of Figure 1 (SEQ ID NO:2) has about 29.5% identity (using BESTFIT (from GCG suite of Programs)) in 294 amino acid residues with Murine tumor necrosis factor receptor 2 (TNF-R2) (M. Lewis et al., Proc Natl Acad. Sci. USA, 88:2830-2834(1991); R.G. Goodwin et al. Mol Cell Biol 11:3020-3026(1991)). Furthermore, TR4 (SEQ ID NO:2) is 29.4% identical to human TNF-R2 over 300 amino acid residues (C.A. Smith et al. Science 248:1019-1023(1990)). TR4 gene of Figure 1 (SEQ ID NO:1) has about 52% identity (using BLAST) in 120 nucleotide residues with Human Tumor necrosis factor receptor 2 related protein mRNA (M. Baens et al. Genomics 16: 214-215 (1993)). Furthermore, TR4 is 58% identical to murine TNF-R2 mRNA over 148 nucleotide-base residues (E.E. Powell et al. Mamm. Genome 5: 726-727 (1994)).

One polynucleotide of the present invention encoding TR4 may be obtained using standard cloning and screening, from a cDNA library derived from mRNA in cells of human keratinocytes, pancreatic tumor, lung endothelium, prostate, cerebellum, fetal heart, retinal pigment epithelium, progesterone treated endometrial stromal cells using the expressed sequence tag (EST) analysis (Adams, M.D. et al. Science (1991) 252:1651-1656; Adams, M.D. et al., Nature, (1992) 355:632-634; Adams, M.D. et al., Nature (1995) 377 Supp 3:174). Polynucleotides of the invention can also be obtained from natural sources such as genomic DNA libraries or can be synthesized using well known and commercially available techniques.

Thus, the nucleotide sequence encoding TR4 polypeptides may be identical over its entire length to the coding sequence in Figure 1 (SEQ ID NO:1), or may be a degenerate form of this nucleotide sequence encoding the polypeptide of SEQ ID NO:2 or may be highly identical to a nucleotide sequence that encodes the polypeptide of SEQ ID NO:2. Preferably, the polynucleotides of the invention contain a nucleotide sequence that is highly identical, at least 80% identical, with a nucleotide sequence encoding a TR4 polypeptide, or at least 80% identical with the encoding nucleotide sequence set forth in Figure 1 (SEQ ID NO: 1), or at least 80% identical to a nucleotide sequence encoding the polypep-

tion of SEQ ID NO:2.

When the polynucleotides of the invention are used for the recombinant production of TR4 polypeptide, the polynucleotide may include the coding sequence for the mature polypeptide or a fragment thereof, by itself; the coding sequence for the mature polypeptide or fragment in reading frame with other coding sequences, such as those encoding a leader or secretory sequence, a pre- or pro- or prepro- protein sequence, or other fusion peptide portions. For example, a marker sequence which facilitates purification of the fused polypeptide can be encoded. In certain preferred embodiments of this aspect of the invention, the marker sequence is a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gentz *et al.*, *Proc Natl Acad Sci USA* (1989) 86:821-824, or is an HA tag. The polynucleotide may also contain non-coding 5' and 3' sequences, such as transcribed, non-translated sequences, splicing and polyadenylation signals, ribosome binding sites and sequences that stabilize mRNA.

Among particularly preferred embodiments of the invention are polynucleotides encoding TR4 polypeptides having the amino acid sequence of set out in Figure 1 (SEQ ID NO:2) and variants thereof.

Further preferred embodiments are polynucleotides encoding TR4 variants that have the amino acid sequence of the TR4 polypeptide of Figure 1 (SEQ ID NO:2) in which several, 5-10, 1-5, 1-3, 1-2 or 1 amino acid residues are substituted, deleted or added, in any combination.

Further preferred embodiments of the invention are polynucleotides that are at least 80% identical over their entire length to a polynucleotide encoding the TR4 polypeptide having the amino acid sequence set out in Figure 1 (SEQ ID NO:2), and polynucleotides which are complementary to such polynucleotides. In this regard, polynucleotides at least 80% identical over their entire length to the same are particularly preferred, and those with at least 90% are especially preferred. Furthermore, those with at least 97% are highly preferred and those with at least 98-99% are most highly preferred, with at least 99% being the most preferred.

The present invention further relates to polynucleotides that hybridize to the herein above-described sequences. In this regard, the present invention especially relates to polynucleotides which hybridize under stringent conditions to the herein above-described polynucleotides. As herein used, the term "stringent conditions" means hybridization will occur only if there is at least 95% and preferably at least 97% identity between the sequences.

Polynucleotides of the invention, which are sufficiently identical to a nucleotide sequence contained in SEQ ID NO: 1, may be used as hybridization probes for cDNA and genomic DNA, to isolate full-length cDNAs and genomic clones encoding TR4 polypeptide and to isolate cDNA and genomic clones of other genes that have a high sequence similarity to the TR4 gene. Such hybridization techniques are known to those of skill in the art. Typically these nucleotide sequences are 70% identical, preferably 80% identical, more preferably 90% identical to that of the referent. The probes generally will comprise at least 15 nucleotides. Preferably such probes will have at least 30 nucleotides and may have at least 50 nucleotides. Particularly preferred probes will range between 30 and 50 nucleotides.

The polynucleotides and polypeptides of the present invention may be employed as research reagents and materials for discovery of treatments and diagnostics to animal and human disease.

#### Vectors, Host Cells, Expression

The present invention also relates to vectors which comprise a polynucleotide or polynucleotides of the present invention and host cells which are genetically engineered with vectors of the invention and to the production of polypeptides of the invention by recombinant techniques. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention.

For recombinant production, host cells can be genetically engineered to incorporate expression systems or portions thereof for polynucleotides of the present invention. Introduction of polynucleotides into host cells can be effected by methods described in many standard laboratory manuals such as Davis *et al.*, *BASIC METHODS IN MOLECULAR BIOLOGY* (1986) and Sambrook *et al.*, *MOLECULAR CLONING: A LABORATORY MANUAL*, 2<sup>ND</sup> ED., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989) such as calcium phosphate transfection, DEAE-dextran mediated transfection, transfection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction or infection.

Representative examples of appropriate hosts include bacterial cells, such as streptococci, staphylococci, *E. coli*, *Streptomyces* and *Bacillus subtilis* cells; fungal cells such as yeast cells and *Aspergillus* cells; insect cells such as *Drosophila* S2 and *Spodoptera* Sf9 cells; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, 293 and Bowes melanoma cells; and plant cells.

A great variety of expression systems can be used. Such systems include, among others, chromosomal, episomal and virus-derived systems, e.g., vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids. The expression systems may contain control regions that regulate as well

as engender expression. Generally, any system or vector suitable to maintain, propagate or express polynucleotides to produce a polypeptide in a host may be used. The appropriate nucleotide sequence may be inserted into an expression system by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook *et al.*, *MOLECULAR CLONING, A LABORATORY MANUAL* (*supra*).

For secretion of the translated protein into the lumen of the endoplasmic reticulum, into the periplasmic space or into the extracellular environment, appropriate secretion signals may be incorporated into the desired polypeptide. These signals may be endogenous to the polypeptide or they may be heterologous signals.

If the TR4 polypeptide is to be expressed for use in screening assays, the polypeptide may be produced at the surface of the cell. In this event, the cells may be harvested prior to use in the screening assay. If TR4 polypeptide is secreted into the medium, the medium can be recovered in order to recover and purify the polypeptide if produced intracellularly, the cells must first be lysed before the polypeptide is recovered.

TR4 polypeptides can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography is employed for purification. Well-known techniques for refolding proteins may be employed to regenerate active conformation when the polypeptide is denatured during isolation and or purification.

#### Diagnostic Assays

This invention also relates to the use of TR4 polynucleotides for use as diagnostic reagents. Detection of a mutated form of TR4 gene associated with a dysfunction will provide a diagnostic tool that can add to or define a diagnosis of a disease or susceptibility to a disease which results from under-expression, over-expression or altered expression of TR4. Individuals carrying mutations in the TR4 gene may be detected at the DNA level by a variety of techniques.

Nucleic acids for diagnosis may be obtained from a subject's cells, such as from blood, urine, saliva, tissue biopsy or autopsy material. The genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR or other amplification techniques prior to analysis. RNA or cDNA may also be used in similar fashion. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to labeled TR4 nucleotide sequences. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures. DNA sequence differences may also be detected by alterations in electrophoretic mobility of DNA fragments in gels with or without denaturing agents or by direct DNA sequencing. See, e.g., Myers *et al.*, *Science* (1985) 230: 1242. Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S1 protection or the chemical cleavage method. See Cotton *et al.*, *Proc Natl Acad Sci USA* (1985) 85: 4397-4401. In another embodiment, an array of oligonucleotides probes comprising TR4 nucleotide sequence or fragments thereof can be constructed to conduct efficient screening of e.g. genetic mutations. Array technology methods are well known and have general applicability and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability (See for example: M.Chee *et al.*, *Science*, Vol 274, pp 610-613 (1996)).

The diagnostic assays offer a process for diagnosing or determining a susceptibility to chronic and acute inflammation, arthritis, septicemia, autoimmune diseases (eg inflammatory bowel disease, psoriasis), transplant rejection, graft vs host disease, infection, stroke, ischemia, acute respiratory disease syndrome, restenosis, brain injury, AIDS, Bone diseases, cancer (eg lymphoproliferative disorders), atherosclerosis, and Alzheimers disease through detection of mutation in the TR4 gene by the methods described.

In addition, chronic and acute inflammation, arthritis, septicemia, autoimmune diseases (eg inflammatory, bowel disease, psoriasis), transplant rejection, graft vs host disease, infection, stroke, ischemia, acute respiratory disease syndrome, restenosis, brain injury, AIDS, Bone diseases, cancer (eg lymphoproliferative disorders), atherosclerosis, and Alzheimers disease can be diagnosed by methods comprising determining from a sample derived from a subject an abnormally decreased or increased level of TR4 polypeptide or TR4 mRNA. Decreased or increased expression can be measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for example, PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods. Assay techniques that can be used to determine levels of a protein, such as an TR4 polypeptide, in a sample derived from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays.

#### Chromosome Assays

The nucleotide sequences of the present invention are also valuable for chromosome identification. The sequence

is specifically targeted to and can hybridize with a particular location on an individual human chromosome. The mapping of relevant sequences to chromosomes according to the present invention is an important first step in correlating those sequences with gene associated disease. Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins University Welch Medical Library). The relationship between genes and diseases that have been mapped to the same chromosomal region are then identified through linkage analysis (coinheritance of physically adjacent genes).

The differences in the cDNA or genomic sequence between affected and unaffected individuals can also be determined. If a mutation is observed in some or all of the affected individuals but not in any normal individuals, then the mutation is likely to be the causative agent of the disease.

#### Antibodies

The polypeptides of the invention or their fragments or analogs thereof, or cells expressing them can also be used as immunogens to produce antibodies immunospecific for the TR4 polypeptides. The term "immunospecific" means that the antibodies have substantially greater affinity for the polypeptides of the invention than their affinity for other related polypeptides in the prior art.

Antibodies generated against the TR4 polypeptides can be obtained by administering the polypeptides or epitope-bearing fragments, analogs or cells to an animal, preferably a nonhuman, using routine protocols. For preparation of monoclonal antibodies, any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler, G. and Milstein, C., *Nature* (1975) 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor *et al.*, *Immunology Today* (1983) 4:72) and the EBV-hybridoma technique (Cole *et al.*, MONOCLONAL ANTIBODIES AND CANCER THERAPY, pp. 77-96, Alan R. Liss, Inc., 1985).

Techniques for the production of single chain antibodies (U.S. Patent No. 4,946,778) can also be adapted to produce single chain antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms including other mammals, may be used to express humanized antibodies.

The above-described antibodies may be employed to isolate or to identify clones expressing the polypeptide or to purify the polypeptides by affinity chromatography.

Antibodies against TR4 polypeptides may also be employed to treat chronic and acute inflammation, arthritis, septicemia, autoimmune diseases (eg inflammatory bowel disease, psoriasis), transplant rejection, graft vs. host disease, infection, stroke, ischemia, acute respiratory disease syndrome, restenosis, brain injury, AIDS, Bone diseases, cancer (eg lymphoproliferative disorders), atherosclerosis and Alzheimers disease among others.

#### Vaccines

Another aspect of the invention relates to a method for inducing an immunological response in a mammal which comprises inoculating the mammal with TR4 polypeptide or a fragment thereof, adequate to produce antibody and/or T cell immune response to protect said animal from chronic and acute inflammation, arthritis, septicemia, autoimmune diseases (eg inflammatory bowel disease, psoriasis), transplant rejection, graft vs. host disease, infection, stroke, ischemia, acute respiratory disease syndrome, restenosis, brain injury, AIDS, Bone diseases, cancer (eg lymphoproliferative disorders), atherosclerosis and Alzheimers disease among others. Yet another aspect of the invention relates to a method of inducing immunological response in a mammal which comprises delivering TR4 gene via a vector directing expression of TR4 polypeptide *in vivo* in order to induce such an immunological response to produce antibody to protect said animal from diseases.

Further aspect of the invention relates to an immunological vaccine formulation (composition) which, when introduced into a mammalian host, induces an immunological response in that mammal to a TR4 polypeptide wherein the composition comprises a TR4 polypeptide or TR4 gene. The vaccine formulation may further comprise a suitable carrier. Since TR4 polypeptide may be broken down in the stomach, it is preferably administered parenterally (including subcutaneous, intramuscular, intravenous, intradermal etc. injection). Formulations suitable for parenteral administration include aqueous and nonaqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents or thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use. The vaccine formulation may also include adjuvant systems for enhancing the immunogenicity of the formulation, such as oil-in water systems and other systems known in the art. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation.



## Screening Assays

The TR4 polypeptide of the present invention may be employed in a screening process for compounds which activate (agonists) or inhibit activation of (antagonists, or otherwise called inhibitors) the TR4 polypeptide of the present invention. Thus, polypeptides of the invention may also be used to assess identify agonist or antagonists from, for example, cells, cell-free preparations, chemical libraries, and natural product mixtures. These agonists or antagonists may be natural substrates, ligands, receptors, etc., as the case may be, of the polypeptide of the present invention; or may be structural or functional mimetics of the polypeptide of the present invention. See Coligan *et al.*, *Current Protocols in Immunology* 1(2):Chapter 5 (1991).

TR4 proteins are ubiquitous in the mammalian host and are responsible for many biological functions, including many pathologies. Accordingly, it is desirous to find compounds and drugs which stimulate TR4 polypeptide on the one hand and which can inhibit the function of TR4 polypeptide on the other hand. In general, agonists are employed for therapeutic and prophylactic purposes for such conditions as chronic and acute inflammation, arthritis, septicemia, autoimmune diseases (eg inflammatory bowel disease, psoriasis), transplant rejection, graft vs. host disease, infection, stroke, ischemia, acute respiratory disease syndrome, restenosis, brain injury, AIDS, Bone diseases, cancer (eg lymphoproliferative disorders), atherosclerosis, and Alzheimers disease. Antagonists may be employed for a variety of therapeutic and prophylactic purposes for such conditions as chronic and acute inflammation, arthritis, septicemia, autoimmune diseases (eg inflammatory bowel disease, psoriasis), transplant rejection, graft vs. host disease, infection, stroke, ischemia, acute respiratory disease syndrome, restenosis, brain injury, AIDS, Bone diseases, cancer (eg lymphoproliferative disorders), atherosclerosis, and Alzheimers disease.

Such screening procedures may involve producing appropriate cells which express the TR4 polypeptide of the present invention on the surface thereof. Such cells include cells from mammals, yeast, *Drosophila* or *E. coli*. Cells expressing the TR4 polypeptide (or cell membrane containing the expressed polypeptide) fused to the membrane and intracellular domains of any single transmembrane receptor, preferably one with a known functional readout upon ligand binding (eg as tyrosine kinase domain) are then contacted with a test compound to observe binding, or stimulation or inhibition of a functional response.

The assays may simply test binding of a candidate compound wherein adherence to the cells bearing the TR4 polypeptide is detected by means of a label directly or indirectly associated with the candidate compound or in an assay involving competition with a labeled competitor. Further, these assays may test whether the candidate compound results in a signal generated by activation of the TR4 polypeptide, using detection systems appropriate to the cells bearing the TR4 polypeptide at their surfaces. Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist by the presence of the candidate compound is observed. Standard methods for conducting such screening assays are well understood in the art.

Alternatively, TR4 may be expressed as a soluble protein, including versions which fuse all or part of TR4 with a convenient partner peptide for which detection reagents are available, eg TR4-IgG fusions, and used in a solid state or solution phase binding assay. For example, the soluble TR4 can be used to detect agonist or antagonist binding directly through changes that can be detected experimentally, eg surface plasmon resonance, nuclear magnetic resonance spectrometry, sedimentation, calorimetry. The soluble TR4 can be used to detect agonist or antagonist binding indirectly by looking for competition of the candidate agonist or antagonist with a ligand whose binding can be detected. Ligand detection methods include antibody recognition, modification of the ligand via radioactive labeling, chemical modification (eg biotinylation) fusion to an epitope tag. Methods include ELISA based assays, immunoprecipitation and scintillation proximity.

Assays similar to those described above using soluble or membrane bound TR4 may also be used to identify and purify the natural ligand(s) of TR4. These ligands may be agonists or antagonists of the receptor.

Examples of potential TR4 polypeptide antagonists include antibodies or, in some cases, oligonucleotides or proteins which are closely related to the ligands, substrates, receptors, etc., as the case may be, of the TR4 polypeptide, e.g., a fragment of the ligands, substrates, receptors or small molecules which bind to the polypeptide of the present invention but do not elicit a response, so that the activity of the polypeptide is prevented.

The TR4 cDNA, protein and antibodies to the protein may also be used to configure assays for detecting the effect of added compounds on the production of TR4 mRNA and protein in cells. For example, an ELISA may be constructed for measuring secreted or cell associated levels of TR4 protein using monoclonal and polyclonal antibodies by standard methods known in the art, and this can be used to discover agents (i.e. antagonists or agonists) which may inhibit or enhance the production of TR4 from suitably manipulated cells or tissues.

## Prophylactic and Therapeutic Methods

This invention provides methods of treating an abnormal conditions related to both an excess of and insufficient amounts of TR4 polypeptide activity

If the activity of TR4 polypeptide is in excess, several approaches are available. One approach comprises administering to a subject an inhibitor compound (antagonist) as hereinabove described along with a pharmaceutically acceptable carrier in an amount effective to inhibit activation by blocking binding of ligands to the TR4 polypeptide, or by inhibiting a second signal, and thereby alleviating the abnormal condition.

In another approach, soluble forms of TR4 polypeptides still capable of binding the ligand in competition with endogenous TR4 polypeptide may be administered. Typical embodiments of such competitors comprise fragments of the TR4 polypeptide.

In still another approach, expression of the gene encoding endogenous TR4 polypeptide can be inhibited using expression blocking techniques. Known such techniques involve the use of antisense sequences, either internally generated or separately administered. See, for example, O'Connor, *J Neurochem* (1991) 56:560 in Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Alternatively, oligonucleotides which form triple helices with the gene can be supplied. See, for example, Lee *et al.*, *Nucleic Acids Res* (1979) 6:3073; Cooney *et al.*, *Science* (1988) 241:456; Dervan *et al.*, *Science* (1991) 251:1360. These oligomers can be administered *per se* or the relevant oligomers can be expressed *in vivo*.

For treating abnormal conditions related to an under-expression of TR4 and its activity, several approaches are also available. One approach comprises administering to a subject a therapeutically effective amount of a compound which activates TR4 polypeptide, i.e., an agonist as described above, in combination with a pharmaceutically acceptable carrier, to thereby alleviate the abnormal condition. Alternatively, gene therapy may be employed to effect the endogenous production of TR4 by the relevant cells in the subject. For example, a polynucleotide of the invention may be engineered for expression in a replication defective retroviral vector, as discussed above. The retroviral expression construct may then be isolated and introduced into a packaging cell transduced with a retroviral plasmid vector containing RNA encoding a polypeptide of the present invention such that the packaging cell now produces infectious viral particles containing the gene of interest. These producer cells may be administered to a subject for engineering cells *in vivo* and expression of the polypeptide *in vivo*. For overview of gene therapy, see Chapter 20, *Gene Therapy and other Molecular Genetic-based Therapeutic Approaches*, (and references cited therein) in Human Molecular Genetics, T Strachan and A P Read, BIOS Scientific Publishers Ltd (1996).

#### Formulation and Administration

Peptides, such as the soluble form of TR4 polypeptides, and agonists and antagonist peptides or small molecules, may be formulated in combination with a suitable pharmaceutical carrier. Such formulations comprise a therapeutically effective amount of the polypeptide or compound, and a pharmaceutically acceptable carrier or excipient. Such carriers include but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. Formulation should suit the mode of administration, and is well within the skill of the art. The invention further relates to pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention.

Polypeptides and other compounds of the present invention may be employed alone or in conjunction with other compounds, such as therapeutic compounds.

Preferred forms of systemic administration of the pharmaceutical compositions include injection, typically by intravenous injection. Other injection routes such as subcutaneous, intramuscular, or intraperitoneal, can be used. Alternative means for systemic administration include transmucosal and transdermal administration using penetrants such as bile salts or fusidic acids or other detergents. In addition, if properly formulated in enteric or encapsulated formulations, oral administration may also be possible. Administration of these compounds may also be topical and/or localized in the form of salves, pastes, gels and the like.

The dosage range required depends on the choice of peptide, the route of administration, the nature of the formulation, the nature of the subject's condition, and the judgment of the attending practitioner. Suitable dosages, however, are in the range of 0.1-100 µg/kg of subject. Wide variations in the needed dosage, however, are to be expected in view of the variety of compounds available and the differing efficiencies of various routes of administration. For example, oral administration would be expected to require higher dosages than administration by intravenous injection. Variations in these dosage levels can be adjusted using standard empirical routines for optimization, as is well understood in the art.

Polypeptides used in treatment can also be generated endogenously in the subject, in treatment modalities often referred to as "gene therapy" as described above. Thus, for example, cells from a subject may be engineered with a polynucleotide, such as a DNA or RNA, to encode a polypeptide *ex vivo*, and for example, by the use of a retroviral plasmid vector. The cells are then introduced into the subject.

## Examples

The examples below are carried out using standard techniques, which are well known and routine to those of skill in the art, except where otherwise described in detail. The examples illustrate, but do not limit the invention.

## Example 1

An EST (EST#1650779; Project ID HKAAW85) with sequence similarity to the human TNF receptor was discovered in a commercial EST database. A search through several overlapping ESTs allowed the selection of the 5' most EST (EST#1663724; Project ID HKABP82), which was completely sequenced. Analysis of the 1164 nucleotide cDNA sequence indicated that it encoded an open reading frame for a novel member of the TNF receptor superfamily and was named TR4. The predicted protein is 300 amino acids long, and contains an amino-terminal hydrophobic signal sequence required for secretion. Cleavage after amino acid #29. This means that the signal sequence is amino acids 1-29 and the mature protein is amino acids 30-300 (ie 271 residues). Furthermore, the protein does not contain a hydrophobic membrane spanning region suggesting that it is a secreted protein. Comparison of TR4 with other TNF receptor family proteins indicates that it has at least three of the cysteine-rich repeats characteristic of the extracellular domains of this family. There is a fourth more weakly related repeat which nevertheless retained several though not all of the most conserved residues.

## Example 2

## Northern blot of TR4.

Various tissues and cell lines were screened for mRNA expression by Northern blot. RNA was prepared from cells and cell lines using Tri-Reagent (Molecular Research Center Inc., Cincinnati, OH), run in denaturing agarose gels (Sambrook et al., Molecular Cloning: a laboratory manual, 2nd Ed. Cold Spring Harbor Lab Press, NY(1989)) and transferred to Zeta-probe nylon membrane (Biorad, Hercules, CA.) via vacuum blotting in 25mM NaOH for 90 min. After neutralization for 5-10 minutes with 1M Tris-HCl, pH 7.5 containing 3M NaCl, the blots were prehybridized with 50% formamide, 8% dextran sulfate, 6XSSPE, 0.1% SDS and 100µg/ml of sheared and denatured salmon sperm DNA for at least 30 min. At 42°C, cDNA probes were labeled with 32P-CTP by random priming (Statagene, La Jolla, CA), briefly denatured with 0.25M NaOH and added to the prehybridization solution. After a further incubation for at least 24h at 42°C the blots were washed in high stringency conditions and exposed to X-ray film.

Very high expression of TR4 RNA was detected in spleen. High expression was also detected in lung. Low expression was detected in thymus and heart. Low but detectable levels were also observed in kidney and prostate. Other tissues evaluated include brain, liver, small intestine and skeletal muscle.

TR4 RNA was not expressed in resting or activated lymphocytes, bone marrow or monocytes. TR4 was highly expressed in aortic endothelial cells. RNA was also detected in HTB11 neuroblastoma cell line. Other cell lines examined include KG1a, HL60, U937, THP1 and Jurkat cells.

The major RNA form is 1.5 kb in size. There appears to be a minor form of 3.5 kb in size. The 1.5 kb RNA was not detected in U937 cells but was highly inducible following stimulation with DMSO (which generally leads to granulocytic differentiation) but not PMA (which generally leads to monocytic differentiation).

Annex to the description

5

SEQUENCE LISTING

10

(1) GENERAL INFORMATION

15

(i) APPLICANT: SmithKline Beecham Corporation

20

(ii) TITLE OF THE INVENTION: Tumor Necrosis Related Receptor; TRM

(iii) NUMBER OF SEQUENCES: 2

(iv) CORRESPONDENCE ADDRESS:

25

(A) ADDRESSEE: F J Cleveland & Company

(B) STREET: 40/43 Chancery Lane

(C) CITY: London

(D) COUNTY:

30

(E) COUNTRY: United Kingdom

(F) POST CODE: WC2A 1JQ

35

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Diskette

(B) COMPUTER: IBM Compatible

(C) OPERATING SYSTEM: DOS

40

(D) SOFTWARE: FastSEQ for Windows Version 2.0

(vi) CURRENT APPLICATION DATA:

45

(A) APPLICATION NUMBER: Unknown

(B) FILING DATE: 04-FEB-1997

(C) CLASSIFICATION: Unknown

50

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER:

(B) FILING DATE:

55

EP 0 861 850 A1

## (VIII) ATTORNEY/AGENT INFORMATION:

- (A) NAME: CRUMP, Julian Richard John  
 (B) GENERAL AUTHORIZATION NUMBER: 37127  
 (C) REFERENCE/DOCKET NUMBER: GH50000

## (IX) TELECOMMUNICATION INFORMATION:

- (A) TELEPHONE: +44 171 405 5875  
 (B) TELEFAX: +44 171 631 0749  
 (C) TELEX:

## (2) INFORMATION FOR SEQ ID NO: 1:

## (1) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1164 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

## (11) MOLECULE TYPE: cDNA

## (12) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

```

TCTACGCTTC AGGCGACGCG TCGGCGACCG CTTCTCTCTG ACATCTCTCT CAGCGACACG 60
ACCTCTCTCT CTGCGCTGCG AGCGCGCTCT TCTCTCTCTT AGCAAGGAGC ATGACCGCGC 120
TGGACGCGCG AGCGCTCTCT CTGCTCTCTT TCTCTCTCTT GCTGCGCTGCC CTGCTGCGCG 180
TGGCGCTCTT AGCGCTCTCT GCGAGAGACG CGCTCTCTCT CTGGGCGGAC GCAGAGACAG 240
TGGAGCTCTT CCGCTCTCTT CAGTCTCTCT TCTCTCTCTT TCTCTCTCTT CCGTCTCTCT 300
GAGAGAGAGC CAGCGCTCTT CAGCGCTCTT TCTCTCTCTT TCTCTCTCTT CCGTCTCTCT 360
TCTCTCTCTT CCGCTCTCTT TCTCTCTCTT TCTCTCTCTT TCTCTCTCTT CCGTCTCTCT 420
CTGCGCTCTT CAGCGCTCTT CCGCTCTCTT TCTCTCTCTT TCTCTCTCTT CCGTCTCTCT 480
CTCTCTCTCT GAGCGCTCTT TCTCTCTCTT CTCTCTCTT CCGTCTCTCT CCGCGCTCTT 540
CGCTCTCTCT CAGCGCTCTT CAGCGCTCTT TCTCTCTCTT TCTCTCTCTT CCGTCTCTCT 600
TCTCTCTCTT GAGCGCTCTT CAGCGCTCTT CTCTCTCTT CCGCTCTCTT CCGCGCTCTT 660
CAGCTCTCTT CTGCGCTCTT AGCGCTCTCT CAGCTCTCTT TCTCTCTCTT CTGCGCTCTT 720
GGGCTCTCTT AGCTCTCTCT TCTCTCTCTT CTCTCTCTT CCGTCTCTCT TCTCTCTCT 780

```

EP 0 861 850 A1

5 TCTCCATCAA GAGGCTGCAG CGGCTGCUGC AGGCCCTCGA GCGCCCGGAG GGCTGGGGTC 840  
 CGACACCAAG GCGGGGCCCC GCGGCCTTGC AGCTGAAGCT GCGTCGGCGG CTCACGGAGC 900  
 TCCTGGGGGC GCAGGACGGG CGGCTGCTGC TCGGCTGCT GCAGGCGCIG CGCGTGGCCA 960  
 CGATGCCCCG GCTGGAGCGG AGCGTCGGTG AGCGCTTCTT CCTGTGCAC TGATCCTGGC 1020  
 CCGCTCTTAT TTATTCTACA TCCTGGCAC CCCACITGCA CTGAAAGAGG CTTTTTTTAA 1080  
 10 AATAGAAGAA ATGAGGTTTC TTAAAGCTTA TTTTATAAA GCTTTTTCTT AAAAAAAAAA 1140  
 AAAAAAAAAA AAAAAAAAAA AAAA 1164

15

20

25

30

35

40

45

50

55

EP 0 861 850 A1

(2) INFORMATION FOR SEQ ID NO: 2:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 300 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

```

Net Arg Ala Leu Glu Gly Pro Gly Leu Ser Leu Leu Cys Leu Val Leu
 1           5           10           15
Ala Leu Pro Ala Leu Leu Pro Val Pro Ala Val Arg Gly Val Ala Glu
 20           25           30
Thr Pro Thr Tyr Pro Trp Arg Asp Ala Glu Thr Gly Glu Arg Leu Val
 35           40           45
Cys Ala Glu Cys Pro Pro Gly Thr Phe Val Gln Arg Pro Cys Arg Arg
 50           55           60
Asp Ser Pro Thr Thr Tyr Glu Pro Cys Pro Pro Arg His Tyr Thr Gln
 65           70           75           80
Phe Trp Asp Tyr Leu Ala Ala Cys His Thr Cys Asn Val Leu Cys Gly
 85           90           95
Glu Arg Glu Glu Glu Ala Arg Ala Cys His Ala Thr His Asn Arg Ala
100           105           110
Cys Arg Cys Arg Thr Gly Pro Phe Ala Ala Ala Gly Phe Cys Leu Glu
115           120           125
His Ala Ser Cys Pro Phe Glu Ala Arg Val Ile Ala Pro Gly Thr Pro
130           135           140
Ser Glu Asn Thr Glu Cys Glu Arg Cys Pro Pro Gly Thr Phe Ser Ala
145           150           155           160
Ser Ser Ser Ser Ser Glu Gly Cys Glu Pro His Arg Asn Cys Thr Ala
165           170           175
Leu Gly Leu Ala Leu Asn Val Trp Gly Ser Ser Ser His Asp Thr Leu
180           185           190

```

26

Cys Thr Ser Cys Thr Gly Phe Pro Leu Ser Thr Arg Val Pro Gly Ala  
 195 200 205  
 5 Glu Glu Cys Glu Arg Ala Val Ile Asp Phe Val Ala Phe Gln Asp Ile  
 210 215 220  
 Ser Ile Lys Arg Leu Gln Arg Leu Leu Gln Ala Leu Glu Ala Pro Glu  
 10 225 230 235 240  
 Gly Trp Gly Pro Thr Pro Arg Ala Gly Arg Ala Ala Leu Gln Leu Lys  
 245 250 255  
 15 Leu Arg Arg Arg Leu Thr Glu Leu Leu Gly Ala Gln Asp Gly Ala Leu  
 260 265 270  
 Leu Val Arg Leu Leu Gln Ala Leu Arg Val Ala Arg Met Pro Gly Leu  
 275 280 285  
 20 Glu Arg Ser Val Arg Glu Arg Phe Leu Pro Val His  
 290 295 300

#### Claims

1. An isolated polynucleotide comprising a nucleotide sequence that has at least 80% identity to a nucleotide sequence encoding the polypeptide of SEQ ID NO:2 or the corresponding fragment thereof; or a nucleotide sequence complementary to said nucleotide sequence.
2. The polynucleotide of claim 1 which is DNA or RNA.
3. The polynucleotide of claim 1 wherein said nucleotide sequence is at least 80% identical to that contained in SEQ ID NO 1.
4. The polynucleotide of claim 3 wherein said nucleotide sequence is contained in SEQ ID NO: 1.
5. The polynucleotide of claim 1 wherein said encoding nucleotide sequence encodes the polypeptide of SEQ ID NO.2 or a fragment thereof.
6. A polynucleotide probe or primer comprising at least 15 contiguous nucleotides of the polynucleotide of claim 3.
7. A DNA or RNA molecule comprising an expression system wherein said expression system is capable of producing a TR4 polypeptide or a fragment thereof having at least 80% identity with a nucleotide sequence encoding the polypeptide of SEQ ID NO 2 or said fragment when said expression system is present in a compatible host cell.
8. A host cell comprising the expression system of claim 7.
9. A process for producing a TR4 polypeptide or fragment comprising culturing a host of claim 8 and under conditions sufficient for the production of said polypeptide or fragment.
10. The process of claim 9 wherein said polypeptide or fragment is expressed at the surface of said cell.
11. Cells produced by the process of claim 10.
12. The process of claim 9 which further includes recovering the polypeptide or fragment from the culture.



## EP 0 861 850 A1

13. A process for producing a cell which produces a TR4 polypeptide or a fragment thereof comprising transforming or transfecting a host cell with the expression system of claim 7 such that the host cell, under appropriate culture conditions, produces a TR4 polypeptide or fragment.
- 5 14. A TR4 polypeptide or a fragment thereof comprising an amino acid sequence which is at least 80% identical to the amino acid sequence contained in SEQ ID NO:2.
15. The polypeptide of claim 14 which comprises the amino acid sequence of SEQ ID NO:2, or a fragment thereof.
- 10 16. A TR4 polypeptide or fragment prepared by the method of claim 12.
17. An antibody immunospecific for the TR4 polypeptide of claim 14.
18. A method for the treatment of a subject in need of enhanced TR4 polypeptide activity comprising:
- 15 (a) administering to the subject a therapeutically effective amount of an agonist to said polypeptide; and/or  
(b) providing to the subject TR4 polynucleotide in a form so as to effect production of said polypeptide activity *in vivo*.
- 20 19. A method for the treatment of a subject having need to inhibit TR4 polypeptide activity comprising:
- (a) administering to the subject a therapeutically effective amount of an antagonist to said polypeptide; and/or  
(b) administering to the subject a nucleic acid molecule that inhibits the expression of the nucleotide sequence encoding said polypeptide; and/or
- 25 (c) administering to the subject a therapeutically effective amount of a polypeptide that competes with said polypeptide for its ligand, substrate, or receptor
20. A process for diagnosing a disease or a susceptibility to a disease in a subject related to expression or activity of TR4 polypeptide in a subject comprising:
- 30 (a) determining the presence or absence of a mutation in the nucleotide sequence encoding said TR4 polypeptide in the genome of said subject; and/or  
(b) analyzing for the presence or amount of the TR4 polypeptide expression in a sample derived from said subject
- 35 21. A method for identifying compounds which bind to TR4 polypeptide comprising:
- (a) contacting cells of claim 11 with a candidate compound; and  
(b) assessing the ability of said candidate compound to bind to said cells.
- 40 22. The method of claim 21 which further includes determining whether the candidate compound effects a signal generated by activation of the TR4 polypeptide at the surface of the cell, wherein a candidate compound which effects production of said signal is identified as an agonist
- 45 23. An agonist identified by the method of claim 22.
24. The method of claim 21 which further includes contacting said cell with a known agonist for said TR4 polypeptide; and  
determining whether the signal generated by said agonist is diminished in the presence of said candidate compound wherein a candidate compound which effects a diminution in said signal is identified as an antagonist
- 50 for said TR4 polypeptide.
25. An antagonist identified by the method of claim 24
- 55

FIGURE 1. Nucleotide and Amino Acid sequence of TR-I (SEQ ID NOS: 1 and 2, respectively.)

SEQ ID No. 1

10	30	50
CCCACGCGTCCGCCCACGCGTCCGCCCACGCGTCCGGGTGGCATGTCCGT CAGGCACAGC		
70	90	110
AGCGT CCTGTGTCCGCGCTGAGCCGCGCTCTCCCTGCTCCAGCAAGGACCATGAGGGCGC		
		MetArgAlaL
130	150	170
TGGAGGGGCCAGGCCGTGTCCGTGCTGTGCTGGTGGTGGCGCTGCCCTGCCCTGCTGCCGG		
euGluGlyProGlyLeuSerLeuLeuCysLeuValLeuAlaLeuProAlaLeuLeuProV		
190	210	230
TGCCGGCTGTACGCGGACTGGCAGAAACACCCACCTACCCCTGGCGGGACGCAGAGACAG		
alProAlaValArgGlyValAlaGluThrProThrTyProTrpArgAspAlaGluThrG		
250	270	290
GCCAGCGGCTGGTGTGGGCCCACTGCCCCCAGGCACCTTTGTGCAGCGGCCGTGCCGCC		
lyGluArgLeuValCysAlaGlnProProGlyThrPheValGlnArgProCysArgA		
310	330	350
GAGACAGCCCCACGACCTGTGGCCCTGTCCACCGCGCCACTACACGCAGTTCTGGAACT		
ArgAspSerProThrThrCysGluProCysProProArgHisTyThrGlnPheTrpAsnT		
370	390	410

EP 0 861 850 A1

ACCTGGAGCCCTGCCCCTACTGCACGCTCCTCTGCGGCGAGCCTGAGGAGGAGGCGACGGG  
 yrLeuGluArgCysArgTyrCysAsnValLeuCysGlyGluArgGluGluGluAlaArgA

430

450

470

CTTGGCAGCCACCCACAGCCCTGCTGCGGCTGTGGCAGCGGCTTCTTGGCGCAGCTG  
 laCysHisAlaThrHisAsnArgAlaCysArgCysArgThrGlyPhePheAlaHisAlaG

490

510

530

GTTTCTGCTTGGAGCAGCATCGGTCCAGCTGGTGGCGGCTGATTGGCCCCGGGCAACC  
 lyPheCysLeuGluHisAlaSerCysProProGlyAlaGlyValIleAlaProGlyThrP

550

570

590

CCAGCCAGAACACCGAGTCCAGCGCTGCCCGCCAGGCACCTTCTCAGCCAGCAGCTCCA  
 roSerGlnAsnThrGlnCysGlnProCysProProGlyThrPheSerAlaSerSerSerS

610

630

650

GCTCAGAGCAGTGGAGCCTGCAACGCACTGGACGGGCGCTGGGCTGGGCTCAATGTGC  
 erSerGlnGlnCysGlnProPheArgAsnCysThrAlaLeuGlyLeuAlaLeuAsnValP

670

690

710

CAGGCTCTTCTTCCGAGCAAGCTGTGCAACAGCTTCACTGGGCTTGGGCTCAGCACCA  
 roGlySerSerSerPheArgThrLeuCysThrSerGlnGlyPheProLeuSerThrA

730

750

770

GGGTACCAGGAGCTGAGGAGTGTCAAGATGCCCTTCACTCACTTTCTGGTTTTCAGGACA  
 roValProGlyAlaGluGluCysGluArgAlaValIleAspPheValAlaPheGlnAspI

790

810

830

TCTCAATCAGAGGTGTGAGGAGCTGTGAGGCGCTTCAAGGCCCCCGAGCGCTGGGCTC  
 leSerIleLysArgIleGlnArgLeuLeuGlnAlaLeuGluAlaProGluGlyTrpGlyP

850	870	890
CGACACCAAGGGCGGGCGGCGGCGCTTGAGCTGAAGCTGCGT CGGCGGCTCACGGAGC		
roThrProArgAlaGlyArgAlaAlaLeuGlnLeuLysLeuArgArgArgLeuThrGluL		
910	930	950
T CCTCGGGGCGCAGGACGGGGCGCTGCTGGTGCGGCTGCTGCAGGCGCTGCGCGTGGCCA		
euLeuGlyAlaGlnAspGlyAlaLeuLeuValArgLeuLeuGlnAlaLeuArgValAlaA		
970	990	1010
GGATGCCCGGGCTGGAGCGGAGCGTCCGTGAGCGCTT CCTCCCTGTGCACTGAT CCTGGC		
rgMetProGlyLeuGluArgSerValArgGluArgPheLeuProValHisEnd		
1030	1050	1070
CCCTCTTATTTATTTCTACATCTTTGGCAACCCCACTGCACTGAAGAGGCCTTTTTTTTA		
1090	1110	1130
ATTAGAGGAAATGAGGTCTATTGAAAGCTTATTTTTATTAAGCTTTTTCTTAAAAA		
1150		
AAAAAAAAAAAAAAAAAAAA		



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number  
EP 98 30 0382

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
X	DATABASE EMBL Accession Number AA025673, 16 August 1996 "The WashU-Merck EST Project" XP002068286 * abstract *	3,4	C07K14/525 C07K14/71 C12N15/11 C12N15/28
P, X	DATABASE EMBL Accession number AA577603, 11 September 1997 "National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index" XP002068287 * abstract *	3,4	
P, X	DATABASE EMBL Accession number AA155646, 18 January 1997 "WashU-NCI human EST Project" XP002068288 * abstract *	3,4	
A	WO 96 28546 A (HUMAN GENOME SCIENCES INC ; GREENE JOHN M (US); FLEISCHMANN ROBERT) 19 September 1996 * page 6, line 9 - page 8, line 13 *	1-26	TECHNICAL FIELDS SEARCHED (Int.Cl.6)
A	WO 95 33051 A (GENENTECH INC) 7 December 1995 * page 3, line 1 - page 6, line 7 *	1-26	C07K C12N A61K
The present search report has been drawn up for all claims			
Place of search MUNICH		Date of completion of the search 16 June 1998	Examiner Halle, F
CATEGORY OF CITED DOCUMENTS		I theory or principle underlying the invention E earlier patent document, but published on or after the filing date O document cited in the application * document cited for other reasons & member of the same patent family, corresponding document	
X particularly relevant if taken alone Y particularly relevant if combined with another document of the same category A technological background C non-written disclosure P intermediate document			